-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lunresertib in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lunresertib in Gastroesophageal (GE) Junction Carcinomas Drug Details: Lunresertib (RP-6306) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Osemitamab (TST-001) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tislelizumab (Baizean) is a humanized monoclonal antibody...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Imbotolimod in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab Imbotolimod in Gastroesophageal (GE) Junction Carcinomas Drug Details: Ttrastuzumab imbotolimod (BDC-1001) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NPX-267 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NPX-267 in Gastroesophageal (GE) Junction Carcinomas Drug Details: NPX-267 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Gastroesophageal (GE) Junction Carcinomas Drug Details: Apatinib Mesylate (Aitan) is an anti-neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SYSA-1801 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SYSA-1801 in Gastroesophageal (GE) Junction Carcinomas Drug Details: SYSA-1801 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TJCLDN-4B in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TJCLDN-4B in Gastroesophageal (GE) Junction Carcinomas Drug Details: TJ-033721 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NC-410 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. NC-410 in Gastroesophageal (GE) Junction Carcinomas Drug Details: NC-410 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas Drug Details: Sitravatinib malate is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IMSA-101 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. IMSA-101 in Gastroesophageal (GE) Junction Carcinomas Drug Details: IMSA-101 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amivantamab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amivantamab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacmilimab in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacmilimab in Gastroesophageal (GE) Junction Carcinomas Drug Details: CX-072 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elzovantinib in Gastroesophageal (GE) Junction Carcinomas
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elzovantinib in Gastroesophageal (GE) Junction Carcinomas Drug Details: Elzovantinib (TPX-0022) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Certepetide in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Certepetide in Gastroesophageal (GE) Junction Carcinomas Drug Details: Certepetide (CEND-1) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Zimberelimab in Gastroesophageal (GE) Junction Carcinomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Zimberelimab in Gastroesophageal (GE) Junction Carcinomas Drug Details:Zimberelimab (Sepalizumab) is a human monoclonal monospecific antibody that belongs...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Venadaparib in Gastroesophageal (GE) Junction Carcinomas
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Venadaparib in Gastroesophageal (GE) Junction Carcinomas Drug Details: IDX-1197 (NOV1401) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tebotelimab in Gastroesophageal (GE) Junction Carcinomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tebotelimab in Gastroesophageal (GE) Junction Carcinomas Drug Details:Tebotelimab (MGD-013) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Gastroesophageal (GE) Junction Carcinomas
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Cabometyx in Gastroesophageal (GE) Junction Carcinomas Drug Details:Cabozantinib s-malate (Cabometyx, Aptimetyx) is a s-malate salt form...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Gastroesophageal (GE) Junction Carcinomas
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Gastroesophageal (GE) Junction Carcinomas Drug Details: Tremelimumab (Imjudo) human monoclonal monospecific antibody...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.